Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARTS-023
- Development stage
- Preclinical
- Lead developer
- Allorion Therapeutics
- Modality
- Small Molecules
01
Overview
ARTS-023 (Allorion Therapeutics): sourced facts only. name: "In enzymatic assay, ARTS-023 potently inhibits the activity of CDK4/CyclinD1 complex with 50% inhibitory concentration (IC50) in the sub-nanomolar range, displaying near 60-fold selectivity against CDK6 and over 130-fold selectivity against other CDKs assessed." [DOI:10.1158/1538-7445.am2025-3026]; target: "In enzymatic assay, ARTS-023 potently inhibits the activity of CDK4/CyclinD1 complex with 50% inhibitory concentration (IC50) in the sub-nanomolar range, displaying near 60-fold selectivity against CDK6 and over 130-fold selectivity against other CDKs assessed." [DOI:10.1158/1538-7445.am2025-3026]; developer: "1Allorion Therapeutics, Guangzhou, China;" [DOI:10.1158/1538-7445.am2025-3026]; modality: "Here we report the development and preclinical characterization of ARTS-023, an orally bioavailable CDK4 inhibitor with high selectivity over CDK6." [DOI:10.1158/1538-7445.am2025-3026]; stage: "In vivo, ARTS-023 exhibited strong anti-tumor activity as a single agent across various ER+ breast cancer xenograft models." [DOI:10.1158/1538-7445.am2025-3026]
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on ARTS-023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARTS-023.